Dan Burgess, Executive Chairman

Dan Burgess is Executive Chairman of Pulmocide. Dan was founder, President and CEO of Rempex Pharmaceuticals, Inc., an antibiotic company that was sold to the Medicines Company. Previously Dan was President and CEO of Mpex Pharmaceuticals, Inc., a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials; the drug was acquired by Aptalis, Inc. in 2011. Dan has also held senior executive positions at a number of other biotechnology companies. He served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion. Dan holds the following external Board seats: Nabriva Therapeutics (Chairman, NASDAQ:NBRV), Atox Bio (Chairman), Cidara Therapeutics (NASDAQ: CDTX) and Arbutus Biopharma (NASDAQ: ABUS). He is also Chairman of Biocom, the life science industry association of California that represents more than 800 member companies.

Dan is a graduate of Stanford University (AB, Economics) and Harvard Business School (MBA).

Dr Lance Berman, Chief Medical Officer

Lance Berman is Chief Medical Officer of Pulmocide and brings over 25 years of experience in clinical development, medical affairs and corporate leadership from his time in big pharma and in the small biotech start-up space. Most recently Lance was Chief Medical Officer and Senior Vice President at Relypsa in the San Francisco Bay area where he was responsible for building and leading the Company’s clinical development, medical affairs and drug safety functions; as well as playing a key role in the preparation and execution of the Company’s IPO. In addition to having worked across multiple therapeutic areas in clinical development, he has also worked closely with commercial teams to secure product reimbursement and to plan and execute product launches. Lance also serves as a Venture Partner at Ysios Capital and sits on the Board of Oxthera.

Lance received his Bachelor of Medicine and Bachelor of Surgery (MB.ChB) degree from the University of Cape Town, South Africa and holds a Master’s in Science in Pharmaceutical Medicine.

Dr Alison Murray, Former Chief Medical Officer

Dr Alison Murray  is a medical virologist with extensive experience in the clinical development of medicines and molecular diagnostics for infectious diseases, having worked previously at The Wellcome Foundation, GlaxoWellcome, Gilead Sciences, Roche Molecular Systems and GSK.

Dr Pete Strong, CSO

Pete is Pulmocide’s Chief Scientific Officer. The majority of Pete’s pharmaceutical industry career between 1980 and 2003 was spent at Glaxo PLC, GlaxoWellcome and GlaxoSmithKline with a focus on respiratory drug discovery and development. Pete co-foundedr Respivert with Garth Rapeport and colleagues in 2007. Following the acquisition in 2010 by Centocor Ortho Biotech, Pete was a member of the small team which licensed the appropriate Respivert intellectual property rights to Topivert Ltd, leading to the successful Series A funding of that company.

Jennifer Cayer, Chief Business Officer

Ms. Cayer has over twenty-five years of biotech, pharmaceutical and medical device experience. She has co-founded several biotech companies that were funded by blue chip venture investors, acquired by global pharmaceutical companies, or became publicly traded companies. She has executed multiple alliances with pharmaceutical and biotech companies worth over $5B including mergers and acquisitions, drug licensing, technology licensing, drug discovery and development collaborations, and company spinouts.

She brings governance experience through her work with corporate and non-profit boards including executive, finance, and governance committees.

Ms. Cayer is currently the Chief Business Officer of Pulmocide, a clinical stage respiratory company. Ms. Cayer was Chief Operating Officer of Rempex Pharmaceuticals acquired by The Medicines Company just two years after the company was founded. While at Rempex, she acquired a commercial stage therapeutic and facilitated the sale of the company. She joined Rempex from Conatus Pharmaceuticals, a company she co-founded and served as the Senior Vice President, Corporate Development. Ms. Cayer led the negotiations for the acquisition of multiple drug candidates from pharmaceutical companies including the acquisition of the Idun subsidiary of Pfizer.

Prior to Conatus, she was the head of Corporate Development for Idun Pharmaceuticals, Inc. Ms. Cayer played a key role in the negotiations leading to the sale of Idun to Pfizer. Prior to Idun, Ms. Cayer spent five years at Isis/Ionis Pharmaceuticals where she served most recently as Vice President, Business Development. She has held various technical, marketing, and operational roles at Gensia and Puritan Bennett (Tyco).

She is a board member of multiple biotech companies and academic research institutes including Matrisys Biosciences, Devacell, University of California, San Diego Cancer Center, and the Biocom Board of Governors. Ms. Cayer is the Founding Chair of the Biocom Global Partnering Conference and a member of Corporate Directors Forum.

Ms. Cayer graduated from University of California, San Diego with a BS in Bioengineering.

Dr David Mantus, President, US Operations

David Mantus, Ph.D. is President, US Operations at Pulmocide. Prior to joining Pulmocide he was Chief Development Officer, and Managing Director, Arsanis Biosciences GmbH, at Arsanis, Inc. He has more than 28 years of drug development experience, including clinical, regulatory and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious disease. Dr. Mantus has led teams responsible for all aspects of product development, from pre-IND through global commercialization and partnering. Prior to Arsanis he held leadership roles in development at Seres Health, Cubist Pharmaceuticals, Shire Biologics, and Procter & Gamble Pharmaceuticals. Dr. Mantus received his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the University of Washington.

Dr Kaz Ito, Director of Biology

Dr Kaz Ito is former Director of Biology at Respivert with an international reputation in COPD and asthma disease research.

Dr Lindsey Cass, Director of Clinical Development

Dr Lindsey Cass was previously Director, Clinical Development at Respivert and GSK and has extensive experience in the Early Phase Clinical Development of inhaled molecules.

Dr Amanda Davis, Project Director

Dr Amanda Davis was previously Director of Project Management at Respivert and GSK.